NCT03354533已完成1 期
Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Orpha Labs
- 入组人数
- 4
- 主要终点
- Decrease in infection frequency
研究概览
简要总结
Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Leukocyte Adhesion Deficiency Type II.
- •Less than 18 years old.
排除标准
- •Diagnosis of any other disease that is not a manifestation of Leukocyte Adhesion Deficiency Type II.
研究组 & 干预措施
Treatment with ORL-1F - L-fucose
Other
干预措施: L-fucose (Drug)
结局指标
主要结局
Decrease in infection frequency
时间窗: 12 months after treatment started
Statistically significant decrease in infection frequency
次要结局
- Decrease in neutrophil count(30 days after treatment started)
研究者
相似试验
Unknown
2 期
Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional AdenocarcinomaGastric CancerNCT03939962Henan Cancer Hospital60
终止
2 期
An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK ViruriaViruriaViremiaNCT01620268Changzheng-Cinkate24
已完成
2 期
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal CancerColorectal CancerNCT02705300Vejle Hospital70
进行中（未招募）
2 期
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerAdvanced Biliary Tract CancerNCT04005339Georgetown University48
已完成
2 期
Salvage mFOLFOX in BTC After Failure of GemcitabineUnresectable Biliary Tract CancerNCT01127555Chung-Ang University30